It is worth noting that Xiangnan Guan et al. [133] recently identified androgen receptor (AR) as an essential element affecting the reactivity of prostate cancer patients to ICI therapy, and revealed the mechanism by which AR modulates antitumor immunity by regulating IFNγ activity. The gene discussed is AR; the disease is prostate cancer.